Authors: Botagoz Aimagambetova, Taylor Ariko, Stacy Merritt, Tatjana Rundek
Categories: Research, Aging, Arterial hypertension, Arterial stiffness, Cognitive decline, Pulse wave velocity
Source: BMC Neurology
Arterial stiffness is a degenerative modification in the arterial wall that significantly affects normal aging. Arterial hypertension is a major risk factor for cerebrovascular impairment. Pulse wave velocity (PWV) is an established gold standard for measuring arterial stiffness. Studies demonstrated that individuals with elevated blood pressure (BP) and PWV are more likely to experience worse cognitive decline compared to those with either condition alone. The aim of this review is to explore the clinical importance of arterial stiffness for cognitive function in older adults with hypertension.
The systematic review was reported following the PRISMA 2020 guidelines and Cochrane protocol and was registered in NIHR PROSPERO. PubMed, Embase, Web of Science, CINAHL, and Cochrane databases were searched for relevant publications up to December 2022. Articles were filtered by age and type of study and only those including a sample size of at least 500 individuals were selected. Screening of abstracts and full-text review of selected articles were carried out through Covidence.
The full-text review included a total of 434 articles. Twenty-eight prospective studies have met the inclusion criteria. Selected studies used PWV as the main measurement of 24 used carotid-femoral, 2 used brachial-ankle, 1 used aortic PWV, and 11 compared different measures. Studies demonstrated a strong association between increased BP and PWV with brain damage and cognitive deterioration among older adults. One study did not find an interaction with hypertension, while another study found that PWV but not BP was associated with cognitive decline. Few studies showed that the association between stiffness and cognitive outcomes was not significant after adjustment for BP. Several authors suggested that cognitive decline induced by stiff vasculature and hypertension benefited from antihypertensive therapy.
The results of this review demonstrated that arterial hypertension is an important factor linking arterial stiffness to cognitive health in older individuals. BP plays a crucial role in brain integrity, whereas PWV was shown to be a strong measure associated with cognitive decline. Together, they can lead to disabling cognitive outcomes. Early screening of stiffness, BP control, and compliance with treatment are essential for cerebrovascular disease prevention.
NIHR PROSPERO registry ID: CRD42022379887.
The online version contains supplementary material available at 10.1186/s12883-024-03905-8.
Keywords: Arterial stiffness, Pulse wave velocity, Arterial hypertension, Cognitive decline, Aging
The lifespan of humans has increased considerably during the last centuries. In the US, the number of adults older than 65 years was 54.1 million (16%) in 2019. By 2060 this number will increase to 25% (cdc.gov, 2022). Hypertension is a well-known risk factor for cerebral and cardiovascular diseases [1–5] and has continued to be a major public health problem for the last decades. Nearly half (47%, or 116 million) of the adults in the United States (US) have elevated BP. Aging is a heterogenic and dynamic process that progressively limits normal functioning and makes people susceptible to disease and death [6]. With advancing age and chronically increased BP, the elasticity of the arterial wall decreases, subsequently causing an increase in PWV. Elevated PWV is associated with the propagation of pulsatile flow to the brain, endothelial injury [7], decreased blood flow [7, 8], and a decreased ability of the brain to adapt to changes in blood flow [8]. This can lead to a decline in cognitive performance [9] and an increased risk of vascular dementia, although it varies between individuals. The incidence of cerebrovascular diseases (CeVD), particularly cerebral small vessel disease (CSVD), increases with extended life expectancy [10, 11], causing disability, mild cognitive impairment (MCI), and dementia [12, 13]. In the US, vascular cognitive impairment and hypertension are the top 5 causes of disability in the population older than 65 years (cdc.gov, 2022). 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) [5] and 2015 American Heart Association (AHA) [14] recommended carotid-femoral PWV (cfPWV) as a gold standard for arterial stiffness research and an independent predictor for fatal and non-fatal cardiovascular events in hypertensive patients [15]. The process of vascular aging is exaggerated by concurred hypertension which has the strongest association with vascular events [16]. High BP, dyslipidemia, diabetes mellitus (DM), obesity, and other traditional cardiovascular risk factors are often not diagnosed timely and thus, remain undertreated or if treated, are poorly controlled [17].
Objectives of this (1) systematically review recent literature on arterial stiffness, hypertension, and cognitive function in aging and establish gaps where future research could be of benefit, (2) propose mechanistic links between arterial stiffness, hypertension, and cognitive function in aging, (3) assess the clinical ability of pulse wave velocity, as the measure of arterial stiffness, to predict cognitive decline in aging, (4) assess the potential of arterial stiffness to serve as a biomarker of cognitive decline.
We searched PubMed, Embase, Cochrane CENTRAL, CINAHL, Web of Science, and Scopus platforms without data or language limits. We included abstracts from the database. The search strategy included a combination of subject headings and text words for the concepts of arterial stiffness, pulse wave velocity, cognitive decline, arterial hypertension, and their synonyms. The supplementary material presents an example of a search strategy in the PubMed database (Supplementary material, Search strategy). The age older than 45 years was used as a filter. There was no limit to the publication date.
We screened all eligible studies, including clinical randomized trials, case-control, cohort, cross-sectional, longitudinal, experimental pilot, and community-based, as well as database analyses.
We included studies published worldwide, studies using PWV and cognitive disorders measurements (neuropsychological tests and neuroimaging), studies on stroke-free and psychiatric disorders-free populations, articles reporting an odds ratio or hazard ratio for the relationship between exposure and outcome, and studies that included at least 500 participants older than 45 years.
The exclusion criteria included studies that used a case report or case-series study design, articles without PWV measurement of arterial stiffness, articles that did not report a statistic for the association between arterial stiffness and cognitive changes, a sample size of less than 500 participants, and participants younger than 45 years.
First, we completed the title and abstract screening to create a primary list. Then, the full texts were screened for additional information to decide if the studies were eligible. The duplicates and irrelevant articles were removed. The first reviewer (BA) assessed the eligibility criteria, and the second reviewer (TA) screened the articles and worked on the PRISMA flowchart and tables. A third reviewer (TR) was brought in to resolve any discrepancies in the selection. All relevant articles were collected in EndNote and screening was completed through the Covidence voting system.
We extracted data from the selected articles using pre-piloted data extraction forms prepared in Excel. The extracted data (1) subject characteristics (sample size, mean age, gender distribution, race and ethnicity distribution, BP), (2) exposure (stiffness measurements [cfPWV, brachial-ankle PWV (baPWV), aortic PWV (aoPWV), carotid-radial PWV (crPWV), or estimated PWV (ePWV)]), (3) outcome information based on neuropsychological tests of cognitive function [Mini-Mental State Examination (MMSE), modified MMSE (3MSE), and Montreal Cognitive Assessment (MoCA)] and imaging-based studies of the brain [computer tomography (CT) and magnetic resonance imaging (MRI)]. We considered appropriate inclusion/exclusion criteria when selecting the published articles.
Arterial hypertension, stiffness, and cognitive function were evaluated using the following measurements, techniques, guidelines, and
Arterial stiffness is an aging process in the arterial wall characterized by degeneration of elastic fibers, an increase in collagenous material, and calcium deposition [19].
2017 ACC/AHA defined stage 1 hypertension as BP at or above 130/80 mmHg, and stage 2 hypertension at or above 140/90 mmHg [20].
MCI is an early stage of memory loss or other cognitive ability loss with the preserved ability to independently perform most activities of daily living; 5–53% of MCI cases progress into dementia, and 15% into Alzheimer’s disease (AD) [11].
Dementia is an impaired ability to remember, think, or make decisions that interfere with daily activities. It is caused by the degeneration and loss of neurons and neuronal connections in the brain. The affected area causes the symptoms of dementia. Dementia is not a part of normal aging. AD is the most common type of dementia [21].
We used the QualSyst tool to evaluate the studies [22]. Scores for the quality assessment of the studies were calculated based on a 14-item checklist provided in the tool (Supplementary material, Table s1). Scoring above 55% was recommended as the quality inclusion threshold the QualSyst.
Table 1 summarizes the chosen studies’ exposure and outcome data. Table 2 differentiates the PWV measurement by type and includes the results. The cognitive outcomes are compared with arterial stiffness to identify any correlations with increased blood pressure. The combined effect measures were not calculated due to the multiple types of neuropsychological tests used to score the outcome.
The PRISMA flow diagram (Fig. 1) was created using the PRISMA 2020 flow diagram template for systematic review [23].
Fig. 1 Flow diagram of the study selection
Each of the included study characteristics, such as study design, follow-up, age, sex, and other variables, as well as outcome, are described in Table 1. Chosen studies were classified
Our team used the QualSyst tool to evaluate the quality of quantitative studies [22] (Supplementary material, Table s1). All selected articles met the recommended threshold.
The review of reports demonstrated an association between hypertension-related arterial stiffness and cognitive dysfunction. Chronically elevated BP causes the arterial wall to be more fibrotic, hypertrophic, and stiff. Subsequently, these structural changes exacerbate vascular remodeling and promote vascular aging [24–28]. Vascular stiffness and elevated BP cause microvascular brain damage [29–31] and contribute to stroke [32, 33], cognitive deterioration [34–36], and vascular dementia [37, 38]. The correlation between arterial stiffness and cognitive decline was reported in multiple studies. Hajjar et al. reported that hypertensive individuals with stiffness had a worse decline in executive function (p = 0.004), working memory (p = 0.039), and memory scores (p = 0.018). Stiffness was a better predictor of cognitive impairment than BP. Also, stiffness explained the association between hypertension and executive function [39]. After adjustment for MAP and hypertensive therapy, a significant association between higher cfPWV with MCI (HR = 1.41, p = 0.01), but not dementia or AD was shown by Pase et al. in the FHS [40]. Nilsson et al. analyzed the association of stiffness with dementia in the Malmo Diet and Cancer Study (MDCS). The results were (1) cross-sectional analysis demonstrated the highly significant association between cfPWV > 13.8 m/s with MMSE (b=-0.37, p = 0.016) and a quick test of cognitive speed (AQT, b = 4.81, p = 0.004) scores [35]; (2) longitudinally, after adjustment the association between cfPWV with prevalent dementia (OR = 0.95, p = 0.40) and incident dementia (OR = 1.0, p = 0.96) was not significant [41]. Watson et al. demonstrated the association between central stiffness and psychomotor speed decline (OR = 1.42) independent of hypertension [42]. Menezes et al. indicated a faster decline in cognitive performance among older adults (verbal fluency test, b=-0.02, p < 0.01) [43]. Araghi et al. showed that higher tertile of cfPWV (> 8.91 m/s) had the highest rate of hypertension (41.6%) and faster cognitive decline (b=-0.06, p = 0.01) [44].
White matter hyperintensities, enlarged PVS, and total cerebral brain volume were brain damage markers in MRI-based studies and considered causes of cognitive decline. The Age, Gene/Environmental Susceptibility Study (AGES-Reykjavik) demonstrated a bidirectional relationship between BP and stiffness associated with brain damage and cognitive impairment. The results showed a significant relationship between elevated cfPWV and microbleeds (OR = 1.12), cerebellar infarct (OR = 1.30), subcortical infarct (OR = 1.30), and memory change (b=-0.071 ± 0.023, p = 0.002, r^2^ = 0.19) [45]. Earlier, in the same study, Mitchel et al. found a significant association between elevated cfPWV with subcortical infarction (HR = 1.62–1.71, p < 0.001), WMHV (b = 0.108 ± 0.045, p = 0.018), and lower memory score (b=-0.095 ± 0.043, p = 0.028) [46]. The Silent Stroke Study in hypertensive individuals reported the association between increased cfPWV and CSVD load (OR = 1.42, p < 0.001), lacunes (OR = 1.51, p = 0.005), and PVS (OR = 1.39, p = 0.001) [47]. Maillard et al. demonstrated in the third-generation offspring of FHS that cfPWV has a direct mediating effect (a = 0.040, p < 0.001) on the association between SBP and free water (a biomarker of cerebral injury contributing to white matter degeneration) [48].
Routine assessment of older hypertensive individuals for cognitive decline was highly recommended to prevent and postpone cognitive burden by 2020 ESH/EGMS (European Geriatric Medicine Society) [49]. At very advanced age, people are prone to episodes of systolic hypotension [50], which, in conjunction with stiff vasculature, may cause severe cognitive impairment [51]. The Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized and Very Aged Population (PARTAGE) study [52] showed that PWV, but not BP, was associated with cognitive decline in institutionalized individuals older than 80 years (r=-0.005, p = 0.88). This is probably due to comorbidities, lower BP, and very low vascular compliance. The worse MMSE at the baseline and in 1 year (-2.20 ± 3.98, p < 0.03 and 21.3 ± 6.0, p < 0.05 respectively) was associated with higher tertile of cfPWV (20.1 ± 4.0) [52]. Antihypertensive therapy consistently showed a significant improvement in BP and PWV levels in individuals with stiff vasculature [53, 54] and cognitive impairment [39, 55].
Endocrinal causes may mediate the association between aging vasculature and cognitive performance. Collin et al. reported the differences between males and females in the MRI-based the larger white matter hyperintensity volume (WMLV) was significantly associated with higher central SBP among females (OR = 1.27, p < 0.05), whereas in males, the higher periventricular WMLV was significantly associated with higher aortic stiffness (OR = 1.48, p < 0.05) [31].
Oxidative stress, vascular inflammation, autoimmunity activation, and atherosclerotic modulation promote arterial aging, cardiovascular events, and stroke [56]. A strong correlation between metabolic factors, neuroinflammatory markers, cerebral microvascular changes, and white matter lesions with cognitive decline was shown through several studies [57]. Global MARE Consortium (Metabolic Syndrome and Artery Research) considered metabolic syndrome as a mechanism explaining vascular aging, which in some individuals predisposes to earlier and in others to healthier vascular aging. The lower pulse wave velocities correspond to healthier vascular aging [58]. Supernormal vascular aging is a protective phenotype of low PWV values. It can be diagnosed in individuals with extremely low arterial stiffness for their age and sex [59]. Some populations, such as Yanomamo Indians, Papua New Guinea, and rural Kenyans, do not have an increased incidence of hypertension with advancing age [60]; they have a good aerobic load, low cholesterol, low sodium, and high fiber carbs diet [61]. Oppositely, early vascular aging syndrome, first described in 2008, explains the effect of premature vascular aging with abnormal arterial function [62, 63].
Increased vascular stiffness elevates cardiovascular risk [64–68] and demonstrates an association of cognitive decline with cardiovascular risk factors [69–72] and multiple end-organ damage [73–76]. Recently, Scuteri A. et al. defined SHATS (systemic hemodynamic atherosclerotic syndrome) as a combination of left ventricular hypertrophy, common carotid artery damage, and chronic kidney disease (CKD) [75–78]. Left ventricle remodeling and fibrosis can cause cerebrovascular hemodynamic changes with cognitive impairment [79] independently of blood pressure [80]. In recently diagnosed hypertensive individuals, stiffness was associated with microalbuminuria related to cerebral microcirculatory changes and, as a result, caused cognitive damage [81]. The Predictors of Arrhythmic and Cardiovascular Risk in End-stage Renal Disease (PACE) study found an association between cfPWV and lower cognitive test scores in end-stage renal disease patients. This association was attenuated after adjustment for DBP: 3MSE score at the baseline (OR = 4.68, p = 0.20) and in 1 year (OR = 0.12, p = 0.43) [78]. In individuals on hemodialysis, stiffness may deteriorate due to progressive calcification in the arterial wall [82]. Stiffness is a risk factor for cardiovascular disease, myocardial infarction, and stroke because of the strong association with atherosclerotic plaques and thickened intima-media [83]. A positive correlation between stiffness and aortic atherosclerosis was also confirmed in the autopsy study [84].
Studies used multiple biomarkers of arterial stiffness other than cfPWV, such as aoPWV, baPWV, crPWV, ePWV, PP, and pressure integrals. Amier et al. used cardiovascular MRI to measure aoPWV. The results showed that the severity and burden of hypertension were directly related to worse CSVD (OR = 1.17, p = 0.003) and cognitive impairment [85]. The baPWV was used to measure stiffness in Japanese [38] and Chinese [30] studies. Taniguchi et al. reported an independent association between the highest and middle tertiles of baPWV with cognitive decline (OR = 2.95 and OR = 2.39 respectively) [38]. Han et al. used MRI-DTI to assess the association of baPWV with white matter the association was significant (p < 0.05), and MMSE scores were worse in those with elevated PWV (b=-0.093, p = 0.011) [30]. Atherosclerosis Risk in Communities (ARIC) study compared central PP with cfPWV, and the results were participants with elevated cfPWV had larger WMH (p < 0.007), smaller total brain volume, lower scores for executive function/processing speed (b=-0.04, p < 0.05) and global performance (b=-0.09, p < 0.05) [86]. Previously, in the same study, among White individuals, those with higher PP showed a higher prevalence of MCI (OR = 1.27) and dementia (OR = 1.76), as well as those with elevated cfPWV and SBP, had a higher prevalence of MCI (OR = 1.27). The estimates variance among Black participants with CSVD was large, and the association between cfPWV, cPP, and cSBP with MCI and dementia was not statistically significant. There was no effect modification by hypertension or diabetes after adjustment [36]. Similarly, in the Baltimore Aging Study, PP and cfPWV were significantly associated with lower cognitive scores (p < 0.05) before clinical symptoms of dementia [87].
Tsao et al. assessed the association between stiffness, measured with cfPWV, MAP, central PP, and neurocognitive outcomes cross-sectionally [88] and longitudinally [55]: increased cfPWV was associated with executive function decline (b=-0.10 ± 0.04, p < 0.05), elevated MAP was associated with larger WMHV (b=-0.07 ± 0.03, p = 0.017). The longitudinal results from the Rotterdam Study reported no association between stiffness and cognitive decline (OR = 0.93), dementia (OR = 0.91), or AD (OR = 0.90) after adjustment for cardiovascular risk factors [89]. Later, the cross-sectional analysis showed that in uncontrolled hypertensive individuals, cfPWV was associated with CSVD: WMLV (difference in volume = 0.09 per SD increase); lacunar infarcts (OR = 1.63), and deep microbleeds (OR = 2.13). However, in the group with controlled BP and without hypertension, there was no association between cfPWV and CSVD [90].
Carotid-radial was compared with carotid-femoral PWV among residents of Madison, Wisconsin, by Zhong et al. The results failed to find an association between crPWV and cognitive scores. However, cfPWV > 12 m/s was significantly associated with lower MMSE (p = 0.005), auditory verbal learning test (p = 0.01), and composite cognition scores (p = 0.04) [91]. The association of cognitive function with XSPI and cfPWV was compared in the Taipei Study. The results reported no significance with cfPWV but a significance with XSPI (OR = 1.30), likely, due to aortic pulsatility load [92]. Similarly, in the Maastrich Study, the aortic but not carotid stiffness was independently associated with worse cognitive scores (b=-0.018) and larger microvascular damage (b=-0.018, p < 0.05) due to increased pulsatility load [93].
The estimation of PWV (ePWV) was calculated using age and BP and showed an association with increased incidence of CeVD in the Kailuan Study (China, n = 98,348) [94], the Systolic Blood Pressure Interventional Trial (SPRINT) (Greece, n = 8,450) [95], Danish Monitoring Trends and Determinants in Cardiovascular Disease (MONICA, n = 2,366) [96], and General Chinese Population Study (n = 7,012) [97]. Heffernan et al. indicated an inverse association between elevated ePWV and lower cognitive digit symbol substitution test scores among Black (b=-3.47, p < 0.001) and White (b=-3.51, p < 0.001) adults [34].
It is important to mention that 24-hour blood pressure fluctuation associated with atherosclerotic arterial stiffness mostly impacts the carotid pool (113) and was suggested as a contributor to vascular dementia and AD [98]. In individuals with masked and white coat hypertension, BP alteration is associated with arterial structure and function, with greater concentric arterial remodeling among women [99].
Cerebral hypoperfusion was established as a cause of cognitive decline in multiple studies [100–102]. Whereas, in the aging population, pathological vascular mechanisms may be masked by parallel biological processes, routine PWV screening was recommended in the middle-aged population [35, 97, 103, 104]. Carotid-femoral PWV was shown as an independent predictor of mortality in individuals with essential hypertension [105], type 2 diabetes [106], and end-stage CKD [106, 107]. A 1 m/s elevation in PWV was significantly associated with 11% elevation of cardiovascular and 12% all-cause mortality [108]. However, PARTAGE [109], Pronostic Cardiovasculaire Optimization Therapeutique en Geriatric Study (PROTEGER) [110], and metanalysis of 17,635 individuals by Ben-Shlomo et al. [111]. showed that after adjustment for cardiovascular risk factors in older adults, PWV was not predictive of future fatal and nonfatal cardiovascular events.
Age a priori is associated with a change in arterial geometry that leads to increased stiffness and blood pressure over time. The carotid-femoral PWV was found to be more predictive of cognitive decline, whereas hypertension plays a crucial role in cerebrovascular function and brain integrity.
Although some studies were included several times, they were conducted at different time points with different population sizes and addressed different research questions. We treated population studies and interventional studies in the same manner and acknowledged that this may be a potential limitation. However, the results seem to converge and lead to similar conclusions.
Arterial stiffness measured with PWV is significantly associated with cognitive decline in aging individuals with chronically elevated BP. The results show that arterial hypertension is one of the most important risk factors in this association. Multiple other factors contribute to the link between hypertension, stiffness, and cognitive dysfunction as well. These factors include hemodynamic, immunologic, metabolic, neuro, and vascular inflammatory processes, as well as cardiac and renal comorbidities. The mechanism behind cerebral damage and cognitive dysfunction is complex and manifests at micro- and macrovascular levels, such as white matter lesions, microinfarcts, microbleeds, enlarged PVS, and cortical atrophy and neurodegeneration.
Aging individuals are among the most vulnerable populations. They are at the highest risk for developing disabling cognitive impairment and sooner death due to multiple vascular risk factors and chronic comorbidities. Our review showed that accelerated arterial stiffness and higher blood pressure significantly lower cognitive abilities and mental functionality and predispose to worse cardiovascular outcomes and CSVD. Reducing the burden of cardio- and cerebrovascular events by lowering risk factors is complex and suboptimal [17]. Therefore, early screening of high-risk individuals, intensive treatment, and effective prevention of vascular risk factors and cognitive decline in the aging population should be implemented to provide a better quality of life, promote personal independence, and reduce social burden and healthcare costs [112, 113].
The goal of this review was achieved. We captured current relevant studies (Objective 1). There is a negative relationship between arterial stiffness and microvascular cerebral impairment with cognitive dysfunction. Further analysis of published longitudinal studies confirmed this negative association. The selected studies demonstrated a strong association between arterial stiffness, measured with pulse wave velocity, and cognitive decline. After controlling for covariates, such as age, sex, and blood pressure, the negative association between arterial stiffness and cognitive function was maintained in 25 studies. The consistency of this association was strengthened by the findings from studies, regardless of the duration of the follow-up periods.
The MDCS [41], Rotterdam [89], and ARIC-NC [36] studies reported no association between cfPWV with MCI, dementia, and AD after adjustment for cardiovascular risk factors. Later, Palta et al. analyzed data from the ARIC-NC study longitudinally and found that higher cfPWV was associated with AD; however, a significant interaction by hypertension was not observed [86]. Factors such as CKD, metabolic syndrome, and genetic predisposition influenced the relationship between cognitive function and arterial stiffness [78].
The Rotterdam Study (2007) with n = 2,767 (4.9% of the total sample size of all analyzed studies) reported no association between stiffness and cognitive decline after adjustment [89]. Later, the cross-sectional analysis indicated a correlation between higher levels of cfPWV and larger volumes of WMH after adjusting for MAP, heart rate, and cardiovascular risk factors [90].
Objective 2 was supported by the following (1) a stiff aorta promotes increased blood flow to the fragile cerebral small vessels contributing to microcirculatory impairment, (2) cerebral hypoperfusion may induce brain damage, such as WMH, lacunar infarcts, etc., and (3) endothelial dysfunction contributes to hypertension and, as a result, to stroke [44].
Clinical use of biomarkers depends on predictive value, technical availability, and cost of the procedure. Importantly, in analyzed studies, the gold standard for arterial stiffness cfPWV, as well as aoPWV, baPWV, and crPWV were measured noninvasively via specialized devices; ePWV was quantified from age and mean arterial pressure. In the prediction of cardiovascular events ePWV cannot substitute but rather be additive to cfPWV: the estimated measure is not predictive in individuals with high risk. Also, the formula of ePWV includes MAP and, therefore, could be influenced by treated hypertension [114]. The MONICA study reported that a 1 m/s increase in ePWV was associated with a 20% increase in mortality risk [115].
Results of the review support Objective earlier screening of cfPWV improves prognoses of cerebrovascular events, cognitive decline, disability, morbidity, and mortality. Adequate treatment, adherence, and compliance can change the prognosis of the patient and reverse the stiffening process. Many decades of attempting to produce drugs that reduce dementia-related neurodegenerative pathways have failed to show significant clinical benefits [116]. Hajjar et al. [39] and Tsao et al. [55] showed that therapeutic management of hypertension-related arterial stiffness was beneficial for cognitive health. A healthy diet and lifestyle modification minimize cognitive decline in the aging population. Factors like high levels of education, body mass index, physical activity, intensive treatment of hypertension, as well as education programs are protective among non-compliant patients. Regular aerobic exercise and reduced sodium intake were clinically effective in the prevention and treatment of arterial stiffness [117].
To support Objective 4, it was found that a group of experts proposed to implement a classification and staging of aging-related diseases, as well as a scoring system of tissue and organ senescence to evaluate patients’ status and guide policy at the World Health Organization and government level [118]. The control of hypertension demands planned collective action and the adoption of actions at the National level [119]. The paradigm of effective prevention should be shifted from traditional risk factors to arterial aging [17]. The proclamation that calls for joint prevention of stroke and dementia, data harmonization, and translation into action was issued by the World Stroke Organization and endorsed by 23 international, regional, and national organizations [120, 121]. The guidelines for standardized clinical evaluation of cognitive function in hypertensive patients were elaborated by a group of experts from ESH and EGMS in 2020 [49].
The results from this review show that arterial stiffness, measured by PWV is a strong predictor of cognitive decline in hypertensive individuals older than 45 years, independent of any specific demographics. Pulse wave velocity is a non-invasive, reliable method to determine arterial stiffness and is a marker of brain health. The earlier onset of cognitive decline is associated with higher progression rates of worse cerebrovascular outcomes. Thus, a PWV assessment could be included as a routine examination for high-risk adults for the prevention of cardiovascular and cognitive events.
The strength of this review is its inclusion of comprehensive prospective studies with substantial sample sizes that were methodologically analyzed prospectively and cross-sectionally. In geographically, racially, and ethnically diverse elderly populations with comorbidities, the influence of arterial stiffness on cognitive health was confirmed. Out of the 28 studies, the majority (23) utilized gold standard carotid-femoral pulse wave velocity (cfPWV) for assessing arterial stiffness. Additionally, studies compared various measures of arterial stiffness, and the longitudinal analyses covered a period of up to 25 years. Furthermore, several studies suggested the beneficial effects of antihypertensive therapy on arterial stiffness and, consequently, on cognitive outcomes.
The limitations of this systematic review (1) the methods and tools used to measure cognitive function varied across the included studies, (2) heterogeneity in outcome measurements was found among the included studies, (3) cause-effect could not be inferred from the cross‐sectional analyses, (4) population sizes from different continents varied across studies, 5) multiple studies were included several times, however, they were conducted at different time points with different population sizes and addressed some different research questions.
Based on this systematic review, it was established that there is a negative association between arterial stiffness and cognitive function among older adults with hypertension. The future direction suggests that early screening of PWV could play a crucial role as a significant clinical biomarker for middle-aged individuals with hypertension and older asymptomatic individuals at high vascular risk for cognitive decline and stroke. It is imperative to implement interventions aimed at reducing and preventing cerebrovascular events in the aging population. This proactive strategy could significantly contribute to improving the overall brain health of at-risk individuals.
The protocol for the systematic review was registered on the NIHR PROSPERO.
Registry ID: CRD42022379887.
A systematic literature review protocol was provided based on the Cochrane Handbook for Systematic Reviews of Interventions, 2022 [122].
The systematic review was based on the PRISMA 2020 An updated guideline for reporting systematic reviews [23].
We would like to thank John Reynolds, MLIS, Jorge E. Perez, MLIS, and Thilani Samarakoon, PhD, MSIS of the Louis Calder Memorial Library at the University of Miami Miller School of Medicine for consulting on the search strategy and review methodology, and Roni Klass, PhD, at the University of Miami Writing Center.
BA collected, synthesized, and analyzed studies. TA worked on the flowchart and tables. SM assisted in the review and writing. TR guided and assessed the process of reviewing and writing. All authors read and approved the final manuscript.
Financial support received from the Evelyn F. McKnight Brain Institute, University of Miami.
Authors’ BA collected, synthesized, and analyzed studies. TA worked on the flowchart and tables. SM assisted in the review and writing. TR guided and assessed the process of reviewing and writing. All authors read and approved the final manuscript.
All data generated during this review are included in this published manuscript. The NIHR PROSPERO protocol is available at https://www.crd.york.ac.uk/PROSPERO/.
Not applicable.
Not applicable.
The authors declare no competing interests.
All data generated during this review are included in this published manuscript. The NIHR PROSPERO protocol is available at https://www.crd.york.ac.uk/PROSPERO/.